KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Change in Cash (2016 - 2025)

Amgen has reported Change in Cash over the past 17 years, most recently at -$316.0 million for Q4 2025.

  • Quarterly results put Change in Cash at -$316.0 million for Q4 2025, down 110.67% from a year ago — trailing twelve months through Dec 2025 was -$2.8 billion (down 376.38% YoY), and the annual figure for FY2025 was -$2.8 billion, down 376.38%.
  • Change in Cash for Q4 2025 was -$316.0 million at Amgen, down from $1.4 billion in the prior quarter.
  • Over the last five years, Change in Cash for AMGN hit a ceiling of $23.9 billion in Q1 2023 and a floor of -$23.8 billion in Q4 2023.
  • Median Change in Cash over the past 5 years was -$303.0 million (2024), compared with a mean of $143.2 million.
  • Biggest five-year swings in Change in Cash: skyrocketed 9305.17% in 2021 and later plummeted 1170.53% in 2023.
  • Amgen's Change in Cash stood at -$4.0 billion in 2021, then skyrocketed by 52.94% to -$1.9 billion in 2022, then plummeted by 1170.53% to -$23.8 billion in 2023, then soared by 112.45% to $3.0 billion in 2024, then plummeted by 110.67% to -$316.0 million in 2025.
  • The last three reported values for Change in Cash were -$316.0 million (Q4 2025), $1.4 billion (Q3 2025), and -$782.0 million (Q2 2025) per Business Quant data.